@article{8616e698942d44d6953a8fe472a42a0d,
title = "Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?",
keywords = "POLO, germline BRCA, olaparib, pancreatic cancer, platinum-based chemotherapy",
author = "Go Nishikawa and Christopher Booth and Vinay Prasad",
note = "Funding Information: Vinay Prasad reports research funding from Arnold Ventures; royalties from Johns Hopkins Press and Medscape; honoraria for grand rounds/lectures from universities, medical centers, nonprofits, and professional societies; consulting for UnitedHealthcare; speaking fees from Evicore; and Patreon backers for his plenary session podcast. The other authors made no disclosures.",
year = "2020",
month = sep,
day = "15",
doi = "10.1002/cncr.32979",
language = "English (US)",
volume = "126",
pages = "4087--4088",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "18",
}